LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Review

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

Nachman S, Ahmed AO, Amanullah F, Becerra M, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling AC, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais BJ, McIlleron HM, McNeeley D, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah SK, Starke JR, Swaminathan S, Wobudeya E, Worrell C
Download
Download
Abstract
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally effective, are hampered by high pill burden, long duration of treatment, coexistent toxic effects, and an overall scarcity of suitable child-friendly formulations. Several new drugs and regimens with promising activity against both drug-susceptible and drug-resistant strains have entered clinical development and are either in various phases of clinical investigation or have received marketing authorisation for adults; however, none have data on their use in children. This consensus statement, generated from an international panel of opinion leaders on childhood tuberculosis and incorporating reviews of published literature from January, 2004, to May, 2014, addressed four key questions: what drugs or regimens should be prioritised for clinical trials in children? Which populations of children are high priorities for study? When can phase 1 or 2 studies be initiated in children? What are the relevant elements of clinical trial design? The consensus panel found that children can be included in studies at the early phases of drug development and should be an integral part of the clinical development plan, rather than studied after regulatory approval in adults is obtained.
Countries
none
Subject Area
tuberculosispediatrics
DOI
10.1016/S1473-3099(15)00007-9
Published Date
01-Jun-2015
PubMed ID
25957923
Languages
English
Journal
Lancet Infectious Diseases
Volume / Issue / Pages
Volume 15, Issue 6, Pages 711-720
Issue Date
01-Jun-2015
Dimensions Badge